On 14th November, investors and life science & healthcare executives descended on London’s famed Old Billingsgate building to attend LSX’s Inv€$tival Showcase, part of Europe’s biggest
A prominent genetics professor at Stanford University in the US has paid $29 million to investors in Nuredis – a biotech that has now been wound up – after a California court found he misre
Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its the
UK biotech Mereo BioPharma is attempting to face down a revolt by Rubric Capital Management – its largest shareholder holding around 14% of the company – which is agitating for changes to i